首页|Pentoxifylline in hepatopulmonary syndrome

Pentoxifylline in hepatopulmonary syndrome

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
  • 维普
AIM:To determine the effects of pentoxifylline (PTX)on clinical manifestations and evaluate arterial blood gas data in hepatopulmonary syndrome (HPS) in children.METHODS:In a pilot study of 10 children with chronic liver disease,who had HPS,20 mg/kg/d PTX was administered for 3 mo.Clinical data and arterial blood gas parameters were evaluated at baseline,the end of the treatment period,and 3 mo after drug discontinuation.RESULTS:Six patients could tolerate PTX,while four patients experienced complications.Among patients who could tolerate PTX,there was a significant increase in arterial oxygen pressure (PaO2) (P =0.02) and oxygen saturation (SaO2) (P =0.04) and alveolar-arterial oxygen gradient (P =0.02) after 3 mo of treatment.Significant decreases in PaO2 (P =0.02) and alveolararterial oxygen gradient (P =0.02) were also seen after drug discontinuation.CONCLUSION:PTX may improve PaO2,SaO2 and alveolar-arterial oxygen gradient in the early stage of HPS.

PentoxifyllineHepatopulmonary syndromeChildArterial oxygen pressureTherapyAlveolar-arterial oxygen gradient

Hamid Reza Kianifar、Maryam Khalesi、Eftekhar Mahmoodi、Monavar Afzal Aghaei

展开 >

Allergy Research Center, Ghaem Medical Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad 91735, Iran

Department of Pediatrics, Ghaem Medical Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad 91735, Iran

Department of Pediatric Cardiology,Ghaem Medical Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad 91735, Iran

Department of Biostatistics, Faculty of Health, Mashhad University of Medical Sciences, Mashhad 91735, Iran

展开 >

2012

10.3748/wjg.v18.i35.4912

世界胃肠病学杂志(英文版)
太原消化病研治中心

世界胃肠病学杂志(英文版)

SCI
影响因子：1.001
ISSN：1007-9327
年,卷(期)：2012.18(35)
  • 3
  • 28